Joost Boeckmans
Overview
Explore the profile of Joost Boeckmans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boeckmans J, Widman L, Shang Y, Strandberg R, Wester A, Schattenberg J, et al.
Eur J Intern Med
. 2025 Feb;
PMID: 39952814
Background: It is unclear if the risk of hepatic decompensation or hepatocellular carcinoma (HCC) differs between patients with compensated alcohol-related liver disease (ALD)- and metabolic dysfunction-associated steatotic liver disease (MASLD)-cirrhosis....
2.
Rodrigues R, Boeckmans J, Vanhaecke T
eGastroenterology
. 2025 Feb;
1(2):e100024.
PMID: 39944003
No abstract available.
3.
Boeckmans J, Prochaska J, Gieswinkel A, Bohm M, Wild P, Schattenberg J
Lancet Reg Health Eur
. 2024 Dec;
48:101153.
PMID: 39687670
Background: The liver-heart axis potentially influences the risk of mortality in patients with heart failure. We aimed to identify the clinical utility of the fibrosis-4 (FIB-4) index in patients with...
4.
Boeckmans J, Michel M, Gieswinkel A, Tuscher O, Konstantinides S, Konig J, et al.
JHEP Rep
. 2024 Oct;
6(10):101171.
PMID: 39380717
Background & Aims: Elevated liver stiffness has been associated with atrial fibrillation (AFib) in the general population. The mechanism underlying this association is unclear. Methods: Participants were recruited from the...
5.
Verhoeven A, van Ertvelde J, Boeckmans J, Gatzios A, Jover R, Lindeman B, et al.
Toxicology
. 2024 Apr;
505:153814.
PMID: 38677583
The field of chemical toxicity testing is undergoing a transition to overcome the limitations of in vivo experiments. This evolution involves implementing innovative non-animal approaches to improve predictability and provide...
6.
Boeckmans J, Sandrin L, Knackstedt C, Schattenberg J
Liver Int
. 2023 Nov;
44(2):344-356.
PMID: 38014628
Metabolic dysfunction-associated steatotic liver disease (MASLD) typically presents with hepatic fibrosis in advanced disease, resulting in increased liver stiffness. A subset of patients further develops liver cirrhosis and hepatocellular carcinoma....
7.
Buyl K, Vrints M, Fernando R, Desmae T, Van Eeckhoutte T, Jans M, et al.
Eur J Pharmacol
. 2023 Aug;
957:175989.
PMID: 37572939
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is characterized by intrahepatic triglyceride accumulation and can progress to metabolic dysfunction-associated steatohepatitis (MASH) and liver...
8.
Boeckmans J, Gatzios A, Schattenberg J, Rodrigues R, Rogiers V, Vanhaecke T
Arch Toxicol
. 2023 May;
97(6):1825-1827.
PMID: 37148318
No abstract available.
9.
Boeckmans J, Schattenberg J
Liver Int
. 2023 Mar;
43(6):1360-1361.
PMID: 36987534
No abstract available.
10.
Iturrospe E, Robeyns R, Da Silva K, van de Lavoir M, Boeckmans J, Vanhaecke T, et al.
Arch Toxicol
. 2023 Feb;
97(5):1335-1353.
PMID: 36826472
Despite the high prevalence of alcoholic liver disease, its identification and characterization remain poor, especially in early stages such as alcoholic fatty liver disease and alcoholic steatohepatitis. This latter implies...